Madrigal Pharmaceuticals (MDGL) Reports Positive Ph3 Results for Resmetirom - Oppenheimer

February 28, 2022 7:05 AM EST Send to a Friend
Oppenheimer analyst Jay Olson reiterated an Outperform rating and $180.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login